|
1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, et al: SEER Cancer Statistics Review,
1975-2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/2014.Accessed.
March 21–2015
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans DB, Farnell MB, Lillemoe KD, Vollmer
C Jr, Strasberg SM and Schulick RD: Surgical treatment of
resectable and borderline resectable pancreas cancer: Expert
consensus statement. Ann Surg Oncol. 16:1736–1744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abrams RA, Lowy AM, O'Reilly EM, Wolff RA,
Picozzi VJ and Pisters PW: Combined modality treatment of
resectable and borderline resectable pancreas cancer, Expert
consensus statement. Ann Surg Oncol. 16:1751–1756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castellanos JA and Merchant NB: Intensity
of follow-up after pancreatic cancer resection. Ann Surg Oncol.
21:747–751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalser MH and Ellenberg SS: Pancreatic
cancer. Histopathology. Arch Surg. 120:899–903. 1985.PubMed/NCBI
|
|
11
|
Bakkevold KE, Arnesjø B, Dahl O and
Kambestad B: Adjuvant combination chemotherapy (AMF) following
radical resection of carcinoma of the pancreas and papilla of
Vater-results of a controlled, prospective, randomized multicentre
study. Eur J Cancer. 29A:698–703. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gastrointestinal Tumor: StudyG roup:
Further evidence of effective adjuvant combined radiation and
chemotherapy following curative resection of pancreatic cancer.
Cancer. 59:2006–2010. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueno H, Kosuge T, Matsuyama Y, Yamamoto J,
Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, et al: A
randomized phase III trial comparing gemcitabine with surgery-only
in patients with resected pancreatic cancer: Japanese study group
of adjuvant therapy for pancreatic cancer. Br J Cancer.
101:908–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herman JM, Swartz MJ, Hsu CC, Winter J,
Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et
al: Analysis of fluorouracil-based adjuvant chemotherapy and
radiation after pancreaticoduodenectomy for ductal adenocarcinoma
of the pancreas: Results of a large, prospectively collected
database at the Johns Hopkins Hospital. J Clin Oncol. 26:3503–3510.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Corsini MM, Miller RC, Haddock MG, Donohue
JH, Farnell MB, Magorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia
S, et al: Adjuvant radiotherapy and chemotherapy for pancreatic
carcinoma: The mayo clinic experience (1975-2005). J Clin Oncol.
26:3511–3516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsu CC, Herman JM, Corsini MM, Winter JM,
Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD,
Wolfgang CL, et al: Adjuvant chemoradiation for pancreatic
adenocarcinoma: The Johns Hopkins Hospital-Mayo clinic
collaborative study. Ann Surg Oncol. 17:981–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stocken DD, Büchler MW, Dervenis C, Bassi
C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H and
Neoptolemos JP: Pancreatic Cancer Meta-analysis Group.
Meta-analysis of randomized adjuvant therapy trials for pancreatic
cancer. Br J Cancer. 92:1372–1381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boeck S, Ankerst DP and Heinemann V: The
role of adjuvant chemotherapy for patients with resected pancreatic
cancer, Systematic review of randomized controlled trials and
meta-analysis. Oncology. 72:314–321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Butturini G, Stocken DD, Wente MN, Jeekel
H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C,
Bassi C, et al: Influence of resection margins and treatment on
survival in patients with pancreatic cancer: Meta-analysis of
randomized controlled trials. Arch Surg. 143:75–83. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao WC, Chien KL, Lin YL, Wu MS, Lin JT,
Wang HP and Tu YK: Adjuvant treatments for resected pancreatic
adenocarcinoma, A systematic review and network meta-analysis.
Lancet Oncol. 14:1095–1103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu Z, Zhong W, Tan ZM, Wang LY and Yuan
YH: Gemcitabine adjuvant therapy for resected pancreatic cancer, A
meta-analysis. Am J Clin Oncol. 38:322–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ren F, Xu YC, Wang HX, Tang L and Ma Y:
Adjuvant chemotherapy, with or without postoperative radiotherapy,
for resectable advanced pancreatic adenocarcinoma, Continue or
stop? Pancreatology. 12:162–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morganti AG, Falconi M, van Stiphout RG,
Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM,
Maidment BW III, et al: Multi-institutional pooled analysis on
adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol
Biol Phys. 90:911–917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khanna A, Walker GR, Livingstone AS,
Arheart KL, Rocha-Lima C and Koniaris LG: Is adjuvant 5-FU-based
chemoradiotherapy for resectable pancreatic adenocarcinoma
beneficial? A meta-analysis of an unanswered question. J
Gastrointest Surg. 10:689–697. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klinkenbijl JH, Jeekel J, Sahmoud T, van
Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT,
Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil
after curative resection of cancer of the pancreas and
periampullary region: Phase III trial of the EORTC gastrointestinal
tract cancer cooperative group. Ann Surg. 230:776–784. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Regine WF, Winter KA, Abrams R, Safran H,
Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA and Willett
CG: Fluorouracil based chemoradiation with either gemcitabine or
fluorouracil chemotherapy following resection of pancreatic
adenocarcinoma. 5-year analysis of the US intergroup/RTOG 9704
phase III trial. Ann Surg Oncol. 18:1319–1326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs. gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Neoptolemos JP, Stocken DD, Smith Tudur C,
Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D and
Büchler MW: Adjuvant 5-fluorouracil and folinic acid vs.
observation for pancreatic cancer Composite data from the ESPAC-1
and −3 (v1) trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raigani S, Ammori J, Kim J and Hardacre
JM: Trends in the treatment of resectable pancreatic
adenocarcinoma. J Gastrointest Surg. 18:113–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y,
Kondo N, Nakagawa N, Sasaki H and Sueda T: Early initiation of
adjuvant chemotherapy improves survival of patients with pancreatic
carcinoma after surgical resection. Cancer Chemother Pharmacol.
71:419–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Valle JW, Palmer D, Jackson R, Cox T,
Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD,
Cunningham D, et al: Optimal duration and timing of adjuvant
chemotherapy after definitive surgery for ductal adenocarcinoma of
the pancreas: Ongoing lessons from the ESPAC-3 study. J Clin Oncol.
32:504–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt J, Abel U, Debus J, Harig S,
Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jäger D, et
al: Open-label, multicenter, randomized phase III trial of adjuvant
chemoradiation plus interferon Alfa-2b versus fluorouracil and
folinic acid for patients with resected pancreatic adenocarcinoma.
J Clin Oncol. 30:4077–4083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fukutomi A, Uesaka K, Boku N, Kanemoto H,
Konishi M, Matsumoto I, et al: JASPAC-01: Randomized phase III
trial of adjuvant chemotherapy with gemcitabine versus S-1 for
patients with resected pancreatic cancer. J Clin Oncol. 31(Suppl):
40082013.
|
|
36
|
Antoniou G, Kountourakis P, Papadimitriou
K, Vassiliou V and Papamichael D: Adjuvant therapy for resectable
pancreatic adenocarcinoma, Review of the current treatment
approaches and future directions. Cancer Treat Rev. 40:78–85. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Evans DB, Ritch PS and Erickson BA:
Neoadjuvant therapy for localized pancreatic cancer, Support is
growing? Ann Surg. 261:18–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Andriulli A, Festa V, Botteri E, Valvano
MR, Koch M, Bassi C, Maisonneuve P and Sebastiano PD:
Neoadjuvant/preoperative gemcitabine for patients with localized
pancreatic cancer, A meta-analysis of prospective studies. Ann Surg
Oncol. 19:1644–1662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gillen S and Schuster T: MeyerZ um
Büschenfelde CM, Friess H and Kleef J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Assifi MM, Lu X, Eibl G, Reber HA, Li G
and Hines OJ: Neoadjuvant therapy in pancreatic adenocarcinoma, A
meta-analysis of phase II trials. Surgery. 150:466–473. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu
XS and Zhang JD: Effect of chemoradiotherapy and neoadjuvant
chemoradiotherapy in resectable pancreatic cancer, A systematic
review and meta-analysis. J Cancer Res Clin Oncol. 140:549–559.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abbott DE, Tzeng CW, Merkow RP, Cantor SB,
Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary
GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is
superior to a surgery-first approach in the treatment of pancreatic
head adenocarcinoma. Ann Surg Oncol. 20((Suppl 3)): S500–S508.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cooper AB, Parmar AD, Riall TS, Hall BL,
Katz MH, Aloia TA and Pitt HA: Does the use of neoadjuvant therapy
for pancreatic adenocarcinoma increase postoperative morbidity and
mortality rates? J Gastrointest Surg. 19:80–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Golcher H, Brunner TB, Witzigmann H, Marti
L, Bechstein W, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG,
Meyer T, et al: Neoadjuvant chemoradiation therapy with
gemcitabine/cisplatin and surgery versus immediate surgery in
resectable pancreatic cancer: Results of the first prospective
randomized phase II trial. Strahlenther Onkol. 191:7–16. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bond-Smith G, Banga N, Hammond TM and
Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Varadhachary GR, Tamm EP, Abbruzzese JL,
Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff
RA: Borderline resectable pancreatic cancer, Definitions,
management and role of preoperative therapy. Ann Surg Oncol.
13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morganti AG, Massaccesi M, La Torre G,
Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M,
Macchia G, et al: A systematic review of resectability and survival
after concurrent chemoradiation in primarily unresectable
pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Laurence JM, Tran PD, Morarji K, Eslick
GD, Lam VW and Sandroussi C: A systematic review and meta-analysis
of survival and surgical outcomes following neoadjuvant
chemoradiotherapy for pancreatic cancer. J Gastrointest Surg.
15:2059–2069. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Petrelli F, Coinu A, Borgonovo KF,
Ghilardi M, Cabiddu M, Cremonesi M, Lonati V and Barni S: Resection
rate with FOLFIRINOX-based neoadjuvant therapy in locally
advanced/borderline resectable pancreatic cancer. A pooled analysis
of published data. Ann Oncol. 25(Suppl 4): iv2402014.
|
|
50
|
Katz MHG, Crane CH and Varadhachary G:
Management of borderline resectable pancreatic cancer. Semin Radiat
Oncol. 24:105–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lopez NE, Prendergast C and Lowy AM:
Borderline resectable pancreatic cancer, Definitions and
management. World J Gastroenterol. 20:10740–10751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Katz MHG, Fleming JB, Bhosale P,
Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW,
Vauthey JN, et al: Response of borderline resectable pancreatic
cancer to neoadjuvant therapy is not reflected by radiographic
indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Festa V, Andriulli A, Valvano MR, Uomo G,
Perri F, Andriulli N, Corrao S and Koch M: Neoadjuvant
chemoradiotherapy for patients with borderline resectable
pancreatic cancer, A meta-analytical evaluation of prospective
studies. JOP. 14:618–625. 2013.PubMed/NCBI
|
|
54
|
Seufferlein T, Laethem JLV, Cutsem EV,
Berlin JD, Büchler M, Cervantes A, et al: The management of locally
advanced pancreatic cancer: European Society of Digestive Oncology
(ESDO) expert discussion and recommendations from the
14th ESMO/World Congress on Gastrointestinal Cancer,
Barcelona. Ann Oncol. 25((Suppl 2)): ii1–ii4. 2014. View Article : Google Scholar
|
|
55
|
Ferrone CR, Marchegiani G, Hong TS, Ryan
DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN,
Blaszkowsky LS, et al: Radiological and surgical implications of
neoadjuvant treatment with FOLFIRINOX for locally advanced and
borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gurusamy KS, Kumar S, Davidson BR and
Fusai G: Resection versus other treatments for locally advanced
pancreatic cancer. Cochrane Database Syst Rev.
2:CD0102442014.PubMed/NCBI
|
|
57
|
Mollberg N, Rahbari NN, Koch M, Hartwig W,
Hoeger Y, Büchler MW and Weitz J: Arterial resection during
pancreatectomy for pancreatic cancer, A systematic review and
meta-analysis. Ann Surg. 254:882–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sultana A, Smith CT, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer.
J Clin Oncol. 25:2607–2615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Burris HA, Moore MJ, Andersen J, Green MR,
Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM,
Tarassoff P, et al: Improvements in survival and clinical benefit
with gemcitabine as first-line therapy for patients with advanced
pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413.
1997.PubMed/NCBI
|
|
60
|
Liang HL: Comparing gemcitabine-based
combination chemotherapy with gemcitabine alone in inoperable
pancreatic cancer: A meta-analysis. J Clin Oncol.
23:41102005.PubMed/NCBI
|
|
61
|
Xie DR, Liang HL, Wang Y and Guo SS:
Meta-analysis of inoperable pancreatic cancer, Gemcitabine combined
with cisplatin versus gemcitabine alone. Chin J Dig Dis. 7:49–54.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sultana A, Smith Tudur C, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer,
Results of secondary end points analyses. Br J Cancer. 99:6–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xie DR, Liang HL, Wang Y, Guo SS and Yang
Q: Meta-analysis on inoperable pancreatic cancer, A comparison
between gemcitabine-based combination therapy and gemcitabine
alone. World J Gastroenterol. 12:6973–6981. 2006.PubMed/NCBI
|
|
64
|
Bria E, Milella M, Gelibter A, Cuppone F,
Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F
and Giannarelli D: Gemcitabine-based combinations for inoperable
pancreatic cancer, Have we made real progress? A meta-analysis of
20 phase 3 trials. Cancer. 110:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y
and Zhang FC: A meta-analysis of gemcitabine containing
chemotherapy for locally advanced and metastatic pancreatic
adenocarcinoma. J Hematol Oncol. 4:112011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sun C, Ansari D, Andersson R and Wu DQ:
Does gemcitabine-based combination therapy improve the prognosis of
unresectable pancreatic cancer? World J Gastroenterol.
18:4944–4958. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li Q, Yan H, Liu W, Zhen H, Yang Y and Cao
B: Efficacy and safety of gemcitabine-fluorouracil combination
therapy in the management of advanced pancreatic cancer, A
meta-analysis of randomized controlled trials. PLoS One.
9:e1043462014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Heinemann V, Labianca R, Hinke A and
Louvet C: Increased survival using platinum analog combined with
gemcitabine as compared to single-agent gemcitabine in advanced
pancreatic cancer, Pooled analysis of two randomized trials, the
GERCOR/GISCAD intergroup study and a German multicenter study. Ann
Oncol. 18:1652–1659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Banu E, Banu A, Fodor A, Landi B, Rougier
P, Chatellier G, Andrieu JM and Oudard S: Meta-analysis of
randomized trials comparing gemcitabine-based doublets versus
gemcitabine alone in patients with advanced and metastatic
pancreatic cancer. Drugs Aging. 24:865–879. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Heinemann V, Boeck S, Hinke A, Labianca R
and Louvet C: Meta-analysis of randomized trials, Evaluation of
benefit from gemcitabine-based combination chemotherapy applied in
advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cunningham D, Chau I, Stocken DD, Valle
JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J,
et al: Phase III randomized comparison of gemcitabine versus
gemcitabine plus capecitabine in patients with advanced pancreatic
cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF,
Ma W and Zhang YD: Gemcitabine-based cytotoxic doublets
chemotherapy for advanced pancreatic cancer, Updated subgroup
meta-analysis of overall survival. Jpn J Clin Oncol. 40:432–441.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ciliberto D, Botta C, Correale P, Rossi M,
Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based
combination therapy in the management of advanced pancreatic
cancer, A meta-analysis of randomized trials. Eur J Cancer.
49:593–603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Eltawil KM, Renfrew PD and Molinari M:
Meta-analysis of phase III randomized trials of molecular targeted
therapies for advanced pancreatic cancer. HPB (Oxford). 14:260–268.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tian W, Ding W, Kim S, Xu X, Pan M and
Chen S: Efficacy and safety profile of combining agents against
epidermal growth factor receptor or vascular endothelium growth
factor receptor with gemcitabine-based chemotherapy in patients
with advanced pancreatic cancer, A meta-analysis. Pancreatology.
13:415–422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Chen L, Zhang M and Luo S: Outcome of
gemcitabine plus molecular targeted agent for treatment of
pancreatic cancer, A meta-analysis of prospective phase III
studies. Tumor Biol. 35:11551–11558. 2014. View Article : Google Scholar
|
|
77
|
Li Q, Yuan Z, Yan H, Wen Z, Zhang R and
Cao B: Comparison of gemcitabine combined with targeted agent
therapy versus gemcitabine monotherapy in the management of
advanced pancreatic cancer. Clin Ther. 36:1054–1063. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Van Loon K, Espinoza AM, Fogeman DR, Wolff
RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T,
Tempero MA, et al: Should combination chemotherapy serve as the
backbone in clinical trials of advanced pancreatic cancer?: A
pooled analysis of phase II trials of gemcitabine-containing
doublets plus bevacizumab. Pancreas. 43:343–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yanagimoto H, Ishii H, Nakai Y, Ozaka M,
Ikari T, Koike K, Ueno H, Ioka T, Satoi S, Sho M, et al: Improved
survival with combined gemcitabine and S-1 for locally advanced
pancreatic cancer: Pooled analysis of three randomized studies. J
Hepatobiliary Pancreat Sci. 21:761–766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ku GY, Haaland BA, Ioka T, Isayama H,
Nakai Y, Cheng AL, Okusaka T and de Lima Lopes G Jr: Meta-analysis
of randomized phase II and phase III trials of gemcitabine
with/without S-1 in Asian patients with advanced pancreatic cancer.
Revista Brasileira de Oncologia Clínica. 10:10–16. 2014.
|
|
81
|
Liu Y, Huang QK, Hong WD, Wu JM and Sun
XC: The addition of S-1 to gemcitabine-based chemotherapy improves
survival with increased toxicity for patients with advanced
pancreatic cancer, Combined meta-analysis of efficacy and safety
profile. Clin Res Hepatol Gastroenterol. 39:254–260. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sultana A, Ghaneh P, Cunningham D,
Starling N, Neoptolemos JP and Smith CT: Gemcitabine based
combination chemotherapy in advanced pancreatic cancer-indirect
comparison. BMC Cancer. 8:1922008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Faris JE, Blaszkowsky LS, McDermott S,
Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen
JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic
cancer: The Massachusetts General Hospital Cancer Center
experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Huguet F, Mukherjee S and Javle M: Locally
advanced pancreatic cancer, The role of definitive
chemoradiotherapy. Clin Oncol (R Coll Radiol). 26:560–568. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tempero MA, Malafa MP, Behrman SW, Benson
AB III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B,
Engebretson A, et al: Pancreatic adenocarcinoma, Version 2.2014:
Featured updates to the NCCN guidelines. J Natl Compr Canc Netw.
12:1083–1093. 2014.PubMed/NCBI
|
|
86
|
Xie J, Yuan J and Lu L: Gemcitabine
fixed-dose rate infusion for the treatment of pancreatic carcinoma,
A meta-analysis of randomized controlled trials. Diagn Pathol.
9:2142014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng
J, Ren H and Hao J: Regional intra-arterial vs. systemic
chemotherapy for advanced pancreatic cancer, A systematic review
and meta-analysis of randomized controlled trials. PLoS One.
7:e408472012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hong GB, Zhou JX, Xu LF, Luo FT, Jang RJ,
Luo JH and Chen YT: Meta-analysis on comparative study of curative
effect between interventional therapy and conventional systemic
venous chemotherapy in moderate and advanced pancreatic cancer. J
Pract Radiol. 4:0222004.
|
|
89
|
Rombouts SJ, Vogel JA, van Santvoort HC,
van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG and
Molenaar IQ: Systematic review of innovative ablative therapies for
the treatment of locally advanced pancreatic cancer. Br J Surg.
102:182–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Moertel CG, Frytak S, Hahn RG, O'Connell
MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS,
Holbrook MA, et al: Therapy of locally unresectable pancreatic
carcinoma: A randomized comparison of high dose (6000 rads)
radiation alone, moderate dose radiation (4000 rads +
5-fluorouracil) and high dose radiation + 5-fluorouracil: The
Gastrointestinal Study Group. Cancer. 48:1705–1710. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Hazel JJ, Thirlwell MP, Huggins M,
Maksymiuk A and MacFarlane JK: Multi-drug chemotherapy with and
without radiation for carcinoma of the stomach and pancreas, A
prospective randomized trial. J Can Assoc Radiol. 32:164–165.
1981.PubMed/NCBI
|
|
92
|
Klaassen DJ, MacIntyre JM, Catton GE,
Engstrom PF and Moertel CG: Treatment of locally unresectable
cancer of the stomach and pancreas, A randomized comparison of
5-fluorouracil alone with radiation plus concurrent and maintenance
5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin
Oncol. 3:373–378. 1985.PubMed/NCBI
|
|
93
|
Treatment of: locally unresectable
carcinoma of the pancreas: C omparison of combined-modality therapy
(chemotherapy plus radiotherapy) to chemotherapy alone.
Histopathology. J Natl Cancer Inst. 80:751–755. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cohen SJ, Dobelbower R Jr, Lipsitz S,
Catalano PJ, Sischy B, Smith TJ and Haller DG: Eastern Cooperative
Oncology Group. A randomized phase III study of radiotherapy alone
or with 5-fluorouracil and mitomycin-C in patients with locally
advanced adenocarcinoma of the pancreas: Eastern Cooperative
Oncology Group study E8282. Int J Radiat Oncol Biol Phys.
62:1345–1350. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Loehrer PJ, Feng Y, Cardenes H, Wagner L,
Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR and
Benson AB III: Gemcitabine alone versus gemcitabine plus
radiotherapy in patients with locally advanced pancreatic cancer.
An Eastern Cooperative Oncology Group trial. J Clin Oncol.
29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chauffert B, Mornex F, Bonnetain F,
Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L,
Azzedine A, et al: Phase III trial comparing intensive induction
chemoradiotherapy (60 Gy, infusional 5-FU and intermittent
cisplatin) followed by maintenance gemcitabine with gemcitabine
alone for locally advanced unresectable pancreatic cancer.
Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol.
19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sultana A, Smith Tudur C, Cunningham D,
Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review,
including meta-analyses, on the management of locally advanced
pancreatic cancer using radiation/combined modality therapy. Br J
Cancer. 96:1183–1190. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huguet F, Girard N, Guerche CS, Henneguin
C, Mornex F and Azria D: Chemoradiotherapy in the management of
locally advanced pancreatic carcinoma, A qualitative systematic
review. J Clin Oncol. 27:2269–2277. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chen Y, Sun XJ, Jiang TH and Mao AW:
Combined radiochemotherapy in patients with locally advanced
pancreatic cancer, A meta-analysis. World J Gastronterol.
19:7461–7471. 2013. View Article : Google Scholar
|
|
100
|
Bernstein M, Kaubisch A, Rosenstein M,
Aparo S, Garg MK, Kalnicki S, Guha C and Ohri N: Chemotherapy alone
versus chemoradiation for unresectable pancreatic cancer, A
meta-analysis. Int J Radiat Oncol Biol Phys. 90((Suppl 2014)):
S363–S364. 2014. View Article : Google Scholar
|
|
101
|
Zhang X, Huang HJ, Feng D, Yang DJ, Wang
CM and Cai QP: Is concomitant radiotherapy necessary with
gemcitabine-based chemotherapy in pancreatic cancer? World J
Gastroenterol. 20:17648–17655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhu CP, Shi J, Chen YX, Xie WF and Lin Y:
Gemcitabine in the chemoradiotherapy for locally advanced
pancreatic cancer, A meta-analysis. Radiother Oncol. 99:108–113.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Huguet F, André T, Hammel P, Artru P,
Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E,
Labianca R, et al: Impact of chemoradiotherapy after disease
control with chemotherapy in locally advanced pancreatic
adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol.
25:326–331. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ko AH, Quivey JM, Venook AP, Bergsland EK,
Dito E, Schillinger B and Tempero MA: A phase II study of
fixed-dose rate gemcitabine plus low-dose cisplatin followed by
consolidative chemoradiation for locally advanced pancreatic
cancer. Int J Radiat Oncol Biol Phys. 68:809–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Krishnan S, Rana V, Janjan NA,
Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans
DB, Wolff RA and Crane CH: Induction chemotherapy selects patients
with locally advanced, unresectable pancreatic cancer for optimal
benefit from consolidative chemoradiation therapy. Cancer.
110:47–55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hammel P, Huguet F, Van Laethem JL,
Goldstein D, Glimelius B, Artru P, et al: Comparison of
chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a
locally advanced pancreatic cancer (LAPC) controlled after 4 months
of gemcitabine with or without erlotinib: Final results of the
international phase III LAP 07 study. J Clin Oncol. 31(Suppl):
LBA40032013.
|
|
107
|
Murphy JD, Chang DT, Abelson J, Daly ME,
Yeung HN, Nelson LM and Koong AC: Cost-effectiveness of modern
radiotherapy techniques in locally advanced pancreatic cancer.
Cancer. 118:1119–1129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Fung MC, Takayama S, Ishiguro H, Sakata T,
Adachi S and Morizane T: Chemotherapy for advanced or metastatic
pancreatic cancer, Analysis of 43 randomized trials in 3 decades
(1974-2002). Gan To Kagaku Ryoho. 30:1101–1111. 2003.(In Japanese).
PubMed/NCBI
|
|
109
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen
JZ, Ding H, Wu XY, Huang YF, Mao C and Tang JL: Gemcitabine plus
erlotinib for advanced pancreatic cancer, A systematic review with
meta-analysis. PLoS One. 8:e575282013. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chan K, Shah K, Lien K, Coyle D, Lam H and
Ko YJ: A Bayesian meta-analysis of multiple treatment comparisons
of systemic regimens for advanced pancreatic cancer. PLoS One.
9:e1087492014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Gresham GK, Wells GA, Gill S, Cameron C
and Jonker DJ: Chemotherapy regimens for advanced pancreatic
cancer, A systematic review and network meta-analysis. BMC Cancer.
14:4712014. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu
M, Ghilardi M and Barni S: Polychemotherapy or gemcitabine in
advanced pancreatic cancer, A meta-analysis. Dig Liver Dis.
46:452–459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Attard CL, Brown S, Alloul K and Moore MJ:
Cost-effectiveness of FOLFIRINOX for first-line treatment of
metastatic pancreatic cancer. Curr Oncol. 21:e41–e51.
2014.PubMed/NCBI
|
